Actively Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Led by Kyverna Therapeutics · Updated on 2026-02-11
70
Participants Needed
1
Research Sites
788 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
CONDITIONS
Official Title
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent for the LTFU study
- Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado, Denver
Denver, Colorado, United States, 80045
Actively Recruiting
Research Team
K
Kyverna Therapeutics
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here